Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer
Purpose
This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.
Condition
- Metastatic Colon Cancer
Eligibility
- Eligible Ages
- Over 19 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Be at least 19 years of age. - Diagnosis of colon cancer - Scheduled to undergo surgical resection
Exclusion Criteria
- Inability to provide informed consent - Pregnancy - Inability to lie still for the imaging study - Weight over 350 lbs., due to the scanner bore size - Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) - Inability to receive Omnipaque (iohexol) iodinated contrast - Inability to receive glucagon - Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent - Allergy to contrast imaging agents - Finding or suspicion of distant metastases on CT
Study Design
- Phase
- Phase 1/Phase 2
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Diagnostic
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental [89Zr]Panitumumab-PET/MRI patients |
All study patients will receive [89Zr]Panitumumab-PET/MRI imaging. |
|
More Details
- Status
- Withdrawn
- Sponsor
- University of Alabama at Birmingham